Viridian Therapeutics (NASDAQ:VRDN) Given New $40.00 Price Target at HC Wainwright

Viridian Therapeutics (NASDAQ:VRDN) had its price objective upped by equities researchers at HC Wainwright from $22.00 to $40.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s price objective points to a potential upside of 37.65% from the company’s current price.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings raised shares of Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 14th. Wall Street Zen cut Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, October 4th. Truist Financial raised their price objective on Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Friday, August 7th. Royal Bank Of Canada boosted their price objective on Viridian Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 22nd. Finally, Needham & Company LLC upped their target price on Viridian Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $39.09.

Viridian Therapeutics Price Performance

Shares of VRDN opened at $29.06 on Thursday. The stock has a market capitalization of $3.29 billion, a P/E ratio of -8.62 and a beta of 1.07. Viridian Therapeutics has a twelve month low of $13.18 and a twelve month high of $34.29. The company has a 50 day moving average of $21.80 and a 200-day moving average of $21.85. The company has a quick ratio of 16.95, a current ratio of 16.95 and a debt-to-equity ratio of 0.43.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.21. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%. The company had revenue of $25.75 million for the quarter, compared to analysts’ expectations of $4.72 million. As a group, equities research analysts forecast that Viridian Therapeutics will post -4.07 EPS for the current fiscal year.

Insider Activity

In related news, insider Jennifer Tousignant sold 14,212 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total value of $348,194.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of VRDN. 71 West Capital Partners grew its position in shares of Viridian Therapeutics by 4.1% in the 3rd quarter. 71 West Capital Partners now owns 22,282 shares of the company’s stock worth $459,000 after buying an additional 882 shares during the last quarter. Fulcrum Asset Management LLP bought a new position in Viridian Therapeutics in the 3rd quarter worth about $97,000. Pictet Asset Management Holding SA boosted its stake in shares of Viridian Therapeutics by 13.5% during the third quarter. Pictet Asset Management Holding SA now owns 12,741 shares of the company’s stock valued at $262,000 after purchasing an additional 1,516 shares in the last quarter. AlphaCentric Advisors LLC purchased a new position in Viridian Therapeutics in the third quarter worth $216,000. Finally, Alps Advisors Inc. raised its position in Viridian Therapeutics by 34.5% during the third quarter. Alps Advisors Inc. now owns 150,078 shares of the company’s stock valued at $3,090,000 after acquiring an additional 38,506 shares in the last quarter.

Key Stories Impacting Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Viridian reported a Q3 loss of $0.81 per share, narrower than analysts’ expected loss of $1.01–$1.02. Revenue of $25.75 million also exceeded the roughly $4.72 million consensus estimate. The EPS loss was nevertheless wider than the $0.34 loss a year earlier. Viridian Q3 results
• Positive Sentiment: Management signaled it is targeting a biologics license application for elegrobart in Q1 2027 and expects Lumvoa’s launch to reach broad coverage within six to nine months—milestones that could strengthen the commercial and pipeline outlook. Elegrobart and Lumvoa outlook
• Positive Sentiment: Needham raised its price target to $38 from $34 and maintained a Buy rating, reflecting a more optimistic analyst view of VRDN’s prospects. Needham price target update
• Negative Sentiment: A Yahoo Finance commentary said VRDN looks overvalued even with its new launch, highlighting valuation as a potential concern after the stock’s strong performance. Valuation commentary

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.